Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 34,000 shares at $141.01 ($4.9M) on 2024-05-29, disclosed to the SEC on 2024-05-31.
Scheduled sale ($4.9M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $141.01 | 1,000 | $141K | 2.9% |
| 2 | $141.73 | 3,013 | $427K | 8.6% |
| 3 | $141.73 | 3,013 | $427K | 8.6% |
| 4 | $142.82 | 1,100 | $157K | 3.2% |
| 5 | $143.94 | 1,500 | $216K | 4.4% |
| 6 | $144.99 | 2,400 |
| $348K |
| 7.0% |
| 7 | $146.02 | 5,581 | $815K | 16.5% |
| 8 | $146.02 | 5,581 | $815K | 16.5% |
| 9 | $146.82 | 2,229 | $327K | 6.6% |
| 10 | $146.82 | 2,229 | $327K | 6.6% |
| 11 | $148.06 | 3,177 | $470K | 9.5% |
| 12 | $148.06 | 3,177 | $470K | 9.5% |
| Total | $145.33 avg | 34,000 | $4.9M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |